Altimmune (ALT) Stock
Clinical stage biotech developing vaccines and treatments. Here's the price, business snapshot, and what's worth knowing about Altimmune in October 2026.
Altimmune Inc (ALT) is a clinical-stage biotechnology company focused on developing immunotherapies and vaccine candidates. As a small-cap business (market cap ~ $356.6M), it primarily derives value from its pipeline and clinical progress rather than steady revenue. Investors should know the stock is catalyst-driven: trial readouts, regulatory decisions and partner deals can produce significant share-price moves. That creates opportunity but also considerable risk — early-stage programmes are binary and timelines can be lengthy. Financial resources, partnerships and trial outcomes will shape valuation and dilution risk. This summary is general information for educational purposes and not personalised investment advice; suitability depends on your goals, risk tolerance and time horizon. Past performance is not indicative of future results and returns are not guaranteed.
